|
|
Article: Dynavax's HEPLISAV Shows Increased Protection Rate for Chronic Kidney Disease Patients.
- Article from:
- Hepatitis Weekly
- Article date:
- November 9, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Dynavax Technologies Corporation (Nasdaq: DVAX) announced the first clinical data for HEPLISAVTM investigational hepatitis B vaccine in chronic kidney disease patients. These data will be presented in a poster session on Saturday, October 31, 2009 at the 47th Annual Meeting of the Infectious Disease Society of America (IDSA) in Philadelphia, Pennsylvania (see also Dynavax Technologies Corporation).
Vaccinated with HEPLISAV, chronic kidney disease patients demonstrated rapid, increased protection against hepatitis B viral infection in fewer doses than patients receiving licensed vaccine. 96% of patients (n = 36) receiving 3 doses of HEPLISAV achieved ...